[Form 4] Cumberland Pharmaceuticals Inc Insider Trading Activity

Rhea-AI Filing Summary

A.J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals (CPIX), reported a series of purchases of the company's common stock executed during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. Transactions recorded in the Form 4 run from July 1 through July 31, 2025 at prices shown in the filing ranging from $3.05 to $3.82.

All reported shares are held directly. After the reported transactions, the Form 4 shows beneficial ownership of 5,699,768 shares. The filing identifies the reporting person as a Director, Chairman and CEO and a 10% owner, and notes the purchases occurred automatically pursuant to the 10b5-1 plan.

Positive

• Insider purchases reported under a Rule 10b5-1 plan, demonstrating increased direct ownership to 5,699,768 shares.
• Transactions occurred across July 2025 at prices explicitly shown in the filing, with a price range of $3.05 to $3.82.

Negative

• None.

Insights

Financial Analyst

TL;DR: CEO purchases executed under a 10b5-1 plan increased direct holdings to 5.70M shares; transactions were routine and systematic.

The Form 4 documents multiple small purchases of common stock throughout July 2025 under a Rule 10b5-1 trading plan adopted November 14, 2024. Prices reported span roughly $3.05 to $3.82, and the ending direct beneficial ownership reported is 5,699,768 shares. From a market-impact perspective, these appear as systematic plan-based purchases rather than opportunistic, one-off buys; the filing does not disclose aggregate dollar value or indicate any derivative trades. Materiality to valuation depends on total outstanding shares, which is not provided in this filing.

Corporate Governance Expert

TL;DR: Insider acquisitions under a pre-existing 10b5-1 plan reinforce existing ownership but are procedural rather than extraordinary.

The report clearly states the purchases were made pursuant to a pre-established Rule 10b5-1 plan, which provides affirmative defense protection. The reporting person is identified as Director, Chairman and CEO and a 10% owner, and the shares are held directly. The filing documents transparent, plan-driven activity across July 2025; there are no derivative positions or sales disclosed that would raise governance or disclosure concerns in this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAZIMI A J

(Last) (First) (Middle)

1600 WEST END AVE.

SUITE 1300

(Street)

NASHVILLE TN 37203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		P	V	16(1)	A	$3.56	5,699,444	D
Common Stock	07/02/2025		P	V	16(1)	A	$3.52	5,699,460	D
Common Stock	07/03/2025		P	V	16(1)	A	$3.31	5,699,476	D
Common Stock	07/07/2025		P	V	16(1)	A	$3.23	5,699,492	D
Common Stock	07/08/2025		P	V	16(1)	A	$3.06	5,699,508	D
Common Stock	07/09/2025		P	V	16(1)	A	$3.05	5,699,524	D
Common Stock	07/10/2025		P	V	16(1)	A	$3.2	5,699,540	D
Common Stock	07/11/2025		P	V	16(1)	A	$3.21	5,699,556	D
Common Stock	07/14/2025		P	V	16(1)	A	$3.46	5,699,572	D
Common Stock	07/15/2025		P	V	16(1)	A	$3.45	5,699,588	D
Common Stock	07/16/2025		P	V	16(1)	A	$3.79	5,699,604	D
Common Stock	07/17/2025		P	V	16(1)	A	$3.82	5,699,620	D
Common Stock	07/18/2025		P	V	16(1)	A	$3.59	5,699,636	D
Common Stock	07/21/2025		P	V	16(1)	A	$3.45	5,699,652	D
Common Stock	07/22/2025		P	V	16(1)	A	$3.47	5,699,668	D
Common Stock	07/23/2025		P	V	16(1)	A	$3.54	5,699,684	D
Common Stock	07/24/2025		P	V	16(1)	A	$3.55	5,699,700	D
Common Stock	07/25/2025		P	V	16(1)	A	$3.37	5,699,716	D
Common Stock	07/28/2025		P	V	13(1)	A	$3.47	5,699,729	D
Common Stock	07/29/2025		P	V	13(1)	A	$3.33	5,699,742	D
Common Stock	07/30/2025		P	V	13(1)	A	$3.55	5,699,755	D
Common Stock	07/31/2025		P	V	13(1)	A	$3.5	5,699,768	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Remarks:

	A.J. Kazimi by /s/ John Hamm as attorney-in-fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did A.J. Kazimi report on the Form 4 for CPIX?

The Form 4 reports multiple purchases of Cumberland Pharmaceuticals common stock made under a Rule 10b5-1 trading plan, increasing direct beneficial ownership to 5,699,768 shares.

When were the insider transactions for CPIX executed?

Transactions listed in the filing were executed between July 1, 2025 and July 31, 2025.

At what prices were the CPIX shares purchased?

The filing shows purchase prices ranging from $3.05 (lowest) to $3.82 (highest) during July 2025.

Were the purchases part of a trading plan?

Yes. The purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.

How is the reported ownership held?

The Form 4 indicates the shares are held directly by the reporting person.

What is the reporting person’s relationship to Cumberland Pharmaceuticals?

The reporting person, A.J. Kazimi, is identified as Director, Chairman and CEO and a 10% owner of the company.